

## **Selected Innovative Medicines in Development as of October 14, 2025**



# Oncology (1 of 3)

## AKEEGA (niraparib/abiraterone)

M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

## IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

## RYBREVANT (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

## CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI (CARTITUDE-5)

## ERLEADA (apalutamide)

High Risk Prostate Cancer (PROTEUS)

## JNJ-1900 (NBTXR3)

Head and Neck Cancer

## RYBREVANT (amivantamab)

Colorectal Cancer 2L (ORIGAMI-3)

## TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

## DARZALEX (daratumumab)

Smoldering Multiple Myeloma (AQUILA)

## IMBRUVICA (ibrutinib)

Frontline Mantle Cell Lymphoma (Triangle)

## RYBREVANT (amivantamab)

Subcutaneous (PALOMA-3)

## CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

## INLEXZO (gemcitabine intravesical system)

Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

## pasritamig

Prostate Cancer

## TALVEY + TECVAYLI

Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

## TALVEY (talquetamab)

TIE NDMM in combination with DR (MajesTEC-7)

## DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

## INLEXZO (gemcitabine intravesical system)

Non Muscle Invasive Bladder Cancer (SunRISe-1)

## Bleximab

Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)

## ERLEADA (apalutamide)

Localized Prostate Cancer (ATLAS)

## INLEXZO (gemcitabine intravesical system)

High Risk Non Muscle Invasive Bladder Cancer BGC Experienced (SunRISe-5)

## RYBREVANT (amivantamab)

Colorectal Cancer (ORIGAMI-2)

## TALVEY (talquetamab)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

## TAR-210 (RIS/erdafitinib)

Intravesical Delivery System for Localized Bladder Cancer (MoonRISe-1)

## Oncology (2 of 3)

### TECVAYLI (teclistamab)

Multiple Myeloma 1-3PLs (MajesTEC-3)

### TECVAYLI (teclistamab)

Relapsed Refractory Multiple Myeloma CD38 exposed  
(MajesTEC-9)

### JNJ-1900 (NBTXR3)

Lung Cancer

### JNJ-0631 (ARX305)

Renal Cancer

### JNJ-2761

Multiple Myeloma

### JNJ-4680

Lung Cancer

### JNJ-5322

Multiple Myeloma

### JNJ-8177 (ARX517)

Prostate Cancer

### TECVAYLI (teclistamab)

TE NDMM maintenance (MajesTEC-4)

### bleximab

Relapsed Refractory Acute Myeloid Leukemia (ALE1001)

### TALVEY + TECVAYLI

Relapsed Refractory Multiple Myeloma (RedirecTT-1)

### JNJ-1493

Hematological Malignancies

### JNJ-3413

Lymphoma

### JNJ-4681

Hematological Malignancies

### JNJ-6420

Prostate Cancer

### JNJ-8377

Lymphoma

### TECVAYLI (teclistamab)

TIE NDMM in combination with DR (MajesTEC-7)

### JNJ-0683 (ARX788)

Breast Cancer

### JNJ-0387

Solid Tumors

### JNJ-2638

Gastrointestinal Cancer

### JNJ-4496

Hematological Malignancies

### JNJ-4916

Lung Cancer

### JNJ-7446

Lung Cancer

### JNJ-8543

Hematological Malignancies

## Oncology (3 of 3)

---

**JNJ-9401**

Prostate Cancer

**JNJ-9530**

Hematological Malignancies

**JNJ-9892**

Hematological Malignancies

**JNJ-9968**

Hematological Malignancies

## icotrokinra

Psoriasis (ICONIC)

## STELARA (ustekinumab)

Pediatric Juvenile Psoriatic Arthritis

## TREMFYA (guselkumab)

Ulcerative Colitis Subcutaneous Induction (ASTRO)

## nipocalimab

Warm Autoimmune Hemolytic Anemia (ENERGY)

## nipocalimab

Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)

## TREMFYA (guselkumab)

Pediatric Ulcerative Colitis (QUASAR JR)

## JNJ-4804 Co-antibody Therapy

Psoriatic Arthritis

## nipocalimab

Systemic Lupus Erythematosus

## SIMPONI (golimumab)

Pediatric Ulcerative Colitis (PURSUIT 2)

## TREMFYA (guselkumab)

Pediatric Psoriasis (PROTOSTAR)

## TREMFYA (guselkumab)

Pediatric Juvenile Psoriatic Arthritis

## nipocalimab

Sjogren's Disease

## STELARA (ustekinumab)

Pediatric Ulcerative Colitis (UNIFI JR)

## icotrokinra

Ulcerative Colitis

## JNJ-4804 Co-antibody Therapy

Crohn's Disease

## nipocalimab

Idiopathic Inflammatory Myopathy

## STELARA (ustekinumab)

Pediatric Crohn's Disease (UNITI JR)

## TREMFYA (guselkumab)

Psoriatic Arthritis Structural Damage (APEX)

## icotrokinra

Psoriatic Arthritis

## nipocalimab

Hemolytic Disease of the Fetus and Newborn (AZALEA)

## TREMFYA (guselkumab)

Pediatric Crohn's Disease (MACARONI-23)

## JNJ-4804 Co-antibody Therapy

Ulcerative Colitis

## JNJ-5939

Atopic Dermatitis

## JNJ-5108

Immunological Diseases

## Immunology (2 of 2)

---

JNJ-6848

Immunological Diseases

JNJ-7528

Atopic Dermatitis

## CAPLYTA (lumateperone)

Adjunctive Treatment for Major Depressive Disorder

## SPRAVATO (esketamine)

Treatment Resistant Depression monotherapy (TRD4005)

## nipocalimab

Chronic Inflammatory Demyelinating Polyneuropathy (ARISE)

## ITI-1284

Generalized Anxiety Disorder

## JNJ-1887 sCD59

Geographic Atrophy

## posdinemab

Alzheimer's Disease (AUTONOMY)

## IMAAVY (nipocalimab)

Generalized Myasthenia Gravis (Vivacity MG3)

## CAPLYTA (lumateperone)

Bipolar Mania

## RPGR Gene Therapy

Retinitis Pigmentosa (LUMEOS)

## ITI-1284

Alzheimer's Disease-Related Psychosis

## JNJ-2056 (tau active immunotherapy) \*

Alzheimer's Disease (RETAIN)

## SPRAVATO (esketamine)

Major Depressive Disorder with Suicidal Ideation

Pediatrics

## IMAAVY (nipocalimab)

Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

## CAPLYTA (lumateperone)

Pediatric Psychiatric Indications

## seltorexant

Adjunctive Treatment for Major Depressive Disorder with Insomnia Symptoms (OARS)

## ITI-1284

Alzheimer's Disease-Related Agitation

## JNJ-5120

Major Depressive Disorder

# Select Other Areas

---

## CABENUVA

HIV Adolescents

## milvexian (Factor Xla)

Secondary Stroke Prevention

## SIRTURO

Leprosy

## UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

## milvexian (Factor Xla)

Acute Coronary Syndrome

## SIRTURO

Tuberculosis Long Acting

## macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

## milvexian (Factor Xla)

Atrial Fibrillation

\*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 14, 2025 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. \*AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sload Kettering; CARVYKTI: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CART-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited